Dey Pharma - Product Pipeline Review - Q4 2010

Date: November 1, 2010
Pages: 40
Price:
US$ 500.00
License [?]:
Publisher: Global Markets Direct
Report type: Company Report
Delivery: E-mail Delivery (PDF)
ID: D2F2C414A2DEN
Leaflet:

Download PDF Leaflet

Dey Pharma - Product Pipeline Review - Q4 2010
Summary

Global Market Direct’s pharmaceuticals report, “Dey Pharma - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. It also gives a complete picture of the company’s future therapy areas of focus.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by Global Markets Direct’s team of industry experts.

Scope

- Dey Pharma - company overview including business description, key employees, and other facts.
- Review of current pipeline of Dey Pharma human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, for the pharmaceutical markets across the globe.
- Product profiles for late stage and clinical stage products of Dey Pharma with complete description of the product’s developmental history, mechanism of action, clinical trials, major milestones and others.
- Recent updates of the Dey Pharma’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Dey Pharma’s strategic position with total access to a detailed intelligence on its product pipeline.
- Assess the growth potential of Dey Pharma in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Dey Pharma’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Dey Pharma.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Dey Pharma and identify potential opportunities in those areas.
- Do deals with an understanding of the mergers and partnerships that have shaped the sector.
1 TABLE OF CONTENTS

1.1 List of Tables
1.2 list of Figures

2 INTRODUCTION
3 DEY PHARMA SNAPSHOT

3.1 Business Description

4 DEY PHARMA- RESEARCH AND DEVELOPMENT OVERVIEW

4.1 Key Therapeutic Areas

5 DEY PHARMA- PIPELINE REVIEW

5.1 Pipeline Products by Stage of Development
5.2 Pipeline Products-Monotherapy
5.3 Pipeline Products-Combination Treatment Modalities

6 DEY PHARMA PIPELINE PRODUCTS GLANCE

6.1 Dey Pharma Phase II Pipeline
6.2 Dey Pharma Phase I Pipeline
6.3 Dey Pharma Pre-Clinical Pipeline

7 DEY PHARMA - DRUG PROFILES

7.1 Product
  7.1.1 Product Description
  7.1.2 Mechanism of Action
  7.1.3 R&D Progress

8 DEY PHARMA PIPELINE ANALYSIS

8.1 Dey Pharma Pipeline Products by Therapeutic Class
8.2 Dey Pharma Pipeline Products by Target
8.3 Dey Pharma Pipeline by Route of Administration
8.4 Dey Pharma Pipeline Products by Molecule Type

9 DEY PHARMA- RECENT PIPELINE UPDATES
10 DEY PHARMA- DORMANT PIPELINE PROJECTS

10.1 Feature on Dormant Projects

11 DEY PHARMA- DISCONTINUED PIPELINE PRODUCTS

11.1 Discontinued Pipeline Product Profiles
  11.1.1 Product

12 DEY PHARMA – FEATURED NEWS
13 DEY PHARMA STATEMENT

13.1 Dey Pharma - Locations and Subsidiaries

14 APPENDIX

14.1 Global Markets Direct Research Methodology
14.2 Coverage
14.3 Secondary Research
14.4 Primary Research
14.5 Models
14.6 Expert Panels
14.7 Contact Us
14.8 Disclaimer

LIST OF TABLES

Table 1: Dey Pharma - Key Information
Table 2: Dey Pharma - Key Facts
Table 3: Dey Pharma - Key Therapeutic Areas
Table 4: Dey Pharma - Pipeline by Stage of Development,
Table 5: Dey Pharma - Monotherapy Products in Pipeline,
Table 6: Dey Pharma - Combination Treatment Modalities in Pipeline,
Table 7: Dey Pharma - Phase II Pipeline,
Table 8: Dey Pharma - Phase I Pipeline,
Table 9: Dey Pharma - Pre-Clinical Pipeline,
Table 10: Dey Pharma - Pipeline By Therapeutic Class
Table 11: Dey Pharma - Pipeline By Target
Table 12: Dey Pharma - Pipeline By Route of Administration
Table 13: Dey Pharma - Pipeline By Molecule Type
Table 14: Dey Pharma - recent Pipeline Updates
Table 15: Dey Pharma - Dormant Pipeline Projects

LIST OF FIGURES

Figure 1: Dey Pharma - Research and Development Overview
Figure 2: Dey Pharma - Pipeline by Stage of Development,
Figure 3: Dey Pharma - Monotherapy Products in Pipeline,
Figure 4: Dey Pharma - Combination Treatment Modalities in Pipeline,
Figure 5: Dey Pharma - Pipeline By Therapeutic Class and Stage of Development
Figure 6: Dey Pharma - Pipeline By Therapeutic Class
Figure 7: Dey Pharma - Pipeline By Target and Stage of Development
Figure 8: Dey Pharma - Pipeline By Target
Figure 9: Dey Pharma - Pipeline By Route of Administration and Stage of Development
Figure 10: Dey Pharma - Pipeline By Route of Administration
Figure 11: Dey Pharma - Pipeline By Molecule Type and Stage of Development
Figure 12: Dey Pharma - Pipeline By Molecule Type

COMPANIES MENTIONED

Dey Pharma
Antares Pharma - Product Pipeline Review - Q4 2010 US$ 500.00 Nov, 2010 · 40 pages
Endotis Pharma - Product Pipeline Review - Q4 2010 US$ 500.00 Dec, 2010 · 27 pages
ERYtech Pharma - Product Pipeline Review - Q4 2010 US$ 500.00 Dec, 2010 · 36 pages
Eusa Pharma - Product Pipeline Review - Q4 2010 US$ 500.00 Nov, 2010 · 40 pages

Ask Your Question

Dey Pharma - Product Pipeline Review - Q4 2010
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: